Sistema de Información Esencial en Terapéutica y Salud

@SIETES7

Última actualización: 21/7/2018
SIETES contiene 92427 citas

 
 
 1 a 10 de 10 
Presentar resultados
Seleccionar todas
1. Cita con resumen
2. Cita con resumen
Anónimo. Outbreak Alert: Potential life-threatening vitamin K-dependent antagonist coagulopathy associated with synthetic cannabinoids use. Centers for Disease Control and Prevention 2018:5 de abril. [Ref.ID 102503]
4. Cita con resumen
Ford BM, Tai S, Fantegrossi WE, Prather PL. Synthetic pot: not your grandfathers marijuana. Trends Pharmacol Sci 2017;38:257-76. [Ref.ID 101989]
5.Tiene citas relacionadas Cita con resumen
Lee SWH, Chaiyakunapruk N, Lai NM. What G6PD-deficient individuals should really avoid. Br J Clin Pharmacol 2017;83:211-2. [Ref.ID 101931]
6. Cita con resumen
Trecki J, Gerona RR, Schwartz MD. Synthetic cannabinoid - Related illnesses and deahts. N Engl J Med 2015;373:103-7. [Ref.ID 99338]
7. Cita con resumen
Law R, Schier J, Martin C, Chang A, Wolkin A. Notes from the field: Increase in reported adverse health effects related to synthetic cannabinoid use — United States, January–May 2015. MMWR Morb Mortal Wkly Rep 2015;64:618-9. [Ref.ID 99193]
8. Cita con resumen
Klumpers LE, Fridberg M, de Kam ML, Little PB, Jensen NO, Kleinloog HD, Elling CE, van Gerven JM. Peripheral selectivity of the novel cannabinoid receptor antagonist TM38837 in healthy subjects. Br J Clin Pharmacol 2013;76:846-57. [Ref.ID 96629]
9. Cita con resumen
Gunderson EW. Synthetic cannabinoids: a new frontier of designer drugs. Ann Intern Med 2013;159:563-4. [Ref.ID 96386]
10.Enlace a cita original
Klumpers LE, Roy C, Ferron G, Turpault S, Poitiers F, Pinquier J-L, van Hasselt JGC, Zuurman L, Erwich FAS, van Gerven JMA. Surinabant, a selective cannabinoid receptor type 1 antagonists, inhibitis delta-9-tetrahydrocannabinol-induced central nervous systsem and heart rate effects in humans. Br J Clin Pharmacol 2013;76:65-77. [Ref.ID 95803]
Seleccionar todas
 
 1 a 10 de 10